Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5626 AL 5640

Case report: Post-traumatic memories triggered by donepezil in a dose-dependent pattern

Wolff ML.

Am J Geriatr Pharmacother. 2012 Jun;10(3):219-22. doi: 10.1016/j.amjopharm.2012.03.001. Epub 2012 Mar 22.

The therapeutic potential of the endocannabinoid system for Alzheimer's disease

Karl T, Cheng D, Garner B, Arnold JC.

Expert Opin Ther Targets. 2012 Apr;16(4):407-20. doi: 10.1517/14728222.2012.671812. Epub 2012 Mar 27.

Cardiac safety of donepezil in elderly patients with Alzheimer disease

Isik AT, Yildiz GB, Bozoglu E, Yay A, Aydemir E.

Intern Med. 2012;51(6):575-8. doi: 10.2169/internalmedicine.51.6671. Epub 2012 Mar 15.

The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update

Bales KR.

Expert Opin Drug Discov. 2012 Apr;7(4):281-97. doi: 10.1517/17460441.2012.666234. Epub 2012 Feb 23.

Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications

Sabbagh JJ, Kinney JW, Cummings JL.

Neurobiol Aging. 2013 Jan;34(1):169-83. doi: 10.1016/j.neurobiolaging.2012.02.027. Epub 2012 Apr 1.

Development of an observer rating scale for caregiver communication in persons with Alzheimer's disease

Williams CL, Parker C.

Issues Ment Health Nurs. 2012 Apr;33(4):244-50. doi: 10.3109/01612840.2011.653040.

Effects of multimodal nondrug therapy on dementia symptoms and need for care in nursing home residents with degenerative dementia: a randomized-controlled study with 6-month follow-up

Luttenberger K, Donath C, Uter W, Graessel E.

J Am Geriatr Soc. 2012 May;60(5):830-40. doi: 10.1111/j.1532-5415.2012.03938.x. Epub 2012 Apr 3.

Engineered antibody approaches for Alzheimer's disease immunotherapy

Robert R, Wark KL.

Arch Biochem Biophys. 2012 Oct 15;526(2):132-8. doi: 10.1016/j.abb.2012.02.022. Epub 2012 Mar 27.

Integrating cytosolic phospholipase A₂ with oxidative/nitrosative signaling pathways in neurons: a novel therapeutic strategy for AD

Sun GY, He Y, Chuang DY, Lee JC, Gu Z, Simonyi A, Sun AY.

Mol Neurobiol. 2012 Aug;46(1):85-95. doi: 10.1007/s12035-012-8261-1. Epub 2012 Apr 3.

Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors

Versijpt J.

Acta Neurol Belg. 2012 Jun;112(2):141-5. doi: 10.1007/s13760-012-0062-9. Epub 2012 Apr 4.

Editorial: Anti Alzheimer agents

Hugel H.

Mini Rev Med Chem. 2012 May;12(5):363. doi: 10.2174/138955712800493889.

Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study

Holthoff V, Ferris S, Gauthier S, Ihl R, Robert P, Winblad B, Sternberg K, Tennigkeit F; ROSA Study Group.

Int J Geriatr Psychiatry. 2013 Feb;28(2):164-72. doi: 10.1002/gps.3805. Epub 2012 Apr 11.

A controlled clinical trial on the effects of exercise on neuropsychiatric disorders and instrumental activities in women with Alzheimer's disease

Nascimento CM, Teixeira CV, Gobbi LT, Gobbi S, Stella F.

Rev Bras Fisioter. 2012 Jun;16(3):197-204. doi: 10.1590/s1413-35552012005000017. Epub 2012 Apr 12.

Recruitment, retention and other methodological issues related to clinical trials for Alzheimer's disease

Vellas B.

J Nutr Health Aging. 2012 Apr;16(4):330. doi: 10.1007/s12603-012-0043-y.

Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial)

Carrié I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, Dantoine T, Rouaud O, Bonnefoy M, Robert P, Cuffi MN, Bories L, Bordes S, Gasnier Y, Desclaux F, Sudres K, Pesce A, Vellas B.

J Nutr Health Aging. 2012 Apr;16(4):355-9. doi: 10.1007/s12603-012-0046-8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias